Fig. 3: Immunophenotyping with percentages and quantitation of CD34⁺ HSPC subsets.

a–c, CD34⁺ HSPCs from day 1 apheresis products, collected following treatment of patients with MM with G-CSF plus either placebo, plerixafor or motixafortide, were purified by immunomagnetic selection and evaluated by multicolor FACS. Each patient (n = 51) contributed a single biologically independent sample examined over one independent experiment per sample/patient. a, t-Distributed stochastic neighbor-embedding (t-SNE) projection of merged flow cytometry file showing nine HSPC subsets based on defined cell surface markers. b, Percentage of CD34⁺ cells within each HSPC subset is shown for patients with MM treated with G-CSF plus either placebo (n = 13), plerixafor (n = 14) or motixafortide (n = 24). c, Absolute numbers (Abs. no.) of each HSPC subset are shown for patients with MM treated with G-CSF plus either placebo (n = 12), plerixafor (n = 12) or motixafortide (n = 24). b,c, Data presented as mean ± s.d. Mean HSPC subset yields were compared using ANOVA followed by a post hoc Tukey–Kramer test for pairwise comparisons among groups. Exact two-sided P values for significant differences are listed.